Skip to main content

Table 1 Characteristics of SpA patients

From: Enhanced BMP-2/BMP-4 ratio in patients with peripheral spondyloarthritis and in cytokine- and stretch-stimulated mouse chondrocytes

 

SpA patients

Total number

56

Age (mean ± SD)

46 ± 16

Male/female

32 (57%)/24

Known duration of the SpA :

46 (82%)

 Average (min-max)

6 years (2 weeks–30 years)

Known HLAB27 status :

39 (70%)

 HLAB27 positive/negative

23 (59%)/16

Known therapeutic treatment :

53 (95%)

 Without therapeutic treatment

13 (25%)

 Treated with NSAIDs

22 (42%)

 Treated with corticosteroids

26 (49%)

 Treated with DMARDs

27 (51%)

 Including anti-TNF-α biotherapies

10 (19%)

  1. NSAIDs nonsteroidal anti-inflammatory drugs, DMARDs disease-modifying antirheumatic drugs